000 a
999 _c8618
_d8618
003 OSt
005 20190514115932.0
008 190324b xxu||||| |||| 00| 0 eng d
040 _aAIKTC-KRRC
_cAIKTC-KRRC
100 _98210
_aSabu, Priyanka
245 _aEfficacy ratio: A tool to enhance optimal antimicrobial use for intra‑abdominal infections
250 _aVol. 50(6), November-December
260 _aMumbai
_bWolter Kluwer
_c2018
300 _a332-335p.
520 _aBACKGROUND: Antimicrobial resistance and inappropriate antibiotic regimen hamper a favorable outcome in intra‑abdominal infections. Clinicians rely on the minimum inhibitory concentration (MIC) value to choose from the susceptible antimicrobials. However, the MIC values cannot be directly compared between the different antibiotics because their breakpoints are different. For that reason, efficacy ratio (ER), a ratio of susceptible MIC breakpoint and MIC of isolate, can be used to choose the most appropriate antimicrobial.MATERIALS AND METHODS: A prospective, observational study conducted during 2015 and 2016 included 356 Escherichiacoli and 158 Klebsiella spp. isolates obtained from the intra‑abdominal specimens. MIC was determined by microbroth dilution method, and ER of each antibiotic was calculated for all the isolates.RESULTS: For both E. coli and Klebsiella spp., ertapenem, amikacin, and piperacillin/tazobactam had the best activities among their respective antibiotic classes.DISCUSSION: This is the first study calculating ER for deciding empiric treatment choices. ER also has a potential additional value in choosing the use of susceptible drugs as monotherapy or combination therapy. A shift in ERs over a period of time tracks rising MIC values and predicts antimicrobial resistance development.CONCLUSION: Estimation of ER could be a meaningful addition for the interpretation of an antimicrobial susceptibility report, thus helping the physician to choose the best among susceptible antimicrobials for patient manageme
650 0 _94774
_aPHARMACOLOGY
653 _aAntimicrobials, , ,
653 _aEfficacy ratio
653 _aErtapenem
653 _aGram‑negative organisms
653 _aMinimum inhibitory concentration
700 _98211
_aElangovan, Divyaa
700 _98212
_aPragasam, Agila Kumari
773 0 _tIndian Journal of Pharmacology
_x0253-7613
_dAndheri - Mumbai Wolters Kluwer India Private Limited
856 _uhttp://www.ijp-online.com/temp/IndianJPharmacol506332-1085263_030052.pdf
_yClick here
942 _2ddc
_cAR